Badgers Ultimately Responsible for Around Half of TB in Cattle, Study Estimates
News Nov 05, 2013
Badgers are ultimately responsible for roughly half of tuberculosis (TB) in cattle in areas with high TB prevalence, according to new estimates based on data from a previous badger culling trial.
However, only around six per cent of infected cattle catch TB from badgers, with onward transmission between cattle herds accounting for the remainder, the study suggests.
The role of badgers in spreading bovine TB has been debated intensely as part of discussions about whether badgers should be culled to control the disease.
The Randomized Badger Culling Trial, which ran from 1998 to 2005, found evidence that culling could reduce TB in herds inside culled areas, while increasing TB in areas nearby.
Mathematical models based on data from the trial were previously used to calculate an estimate of the proportion of TB in cattle that could ultimately be attributed to transmission from badgers.
The new paper, by scientists at Imperial College London, provides a more detailed analysis. It estimates that badgers ultimately account for 52 per cent of cattle TB in areas where prevalence in cattle is high.
There is considerable uncertainty around this estimate, but the authors say that 38 per cent is a robust minimum value for the estimate. There is no robust maximum value.
Professor Christl Donnelly, from the Medical Research Council Centre for Outbreak Analysis and Modelling at Imperial, said: "These findings confirm that badgers do play a large role in the spread of bovine TB. These figures should inform the debate, even if they don't point to a single way forward."
The mathematical model suggested that 5.7 per cent of transmission to cattle herds is from badgers to cattle, with the rest of the contribution from badgers resulting from onward transmission between cattle herds.
Huntsman Cancer Institute Joins National Clinical Trial Targeting AMLNews
Huntsman Cancer Institute (HCI) at the University of Utah (U of U) has been selected to participate in the Beat AML Master Trial, an innovative clinical trial sponsored by The Leukemia & Lymphoma Society (LLS). The clinical trial is testing several new targeted therapies for the treatment of patients with acute myeloid leukemia (AML). HCI is the only facility in the Mountain West offering this trial to AML patients.READ MORE
Study Extends Potential of Personalized Cell-based ImmunotherapiesNews
New methods developed for the study could be applied to devise personalized, cell-based immunotherapies for epithelial ovarian cancer or other types of tumorsREAD MORE
Hope for Hot Flushes: New Class of Menopause Drugs Reduces SeverityNews
A new class of experimental drugs reduces hot flushes in menopausal women by almost three-quarters in just three days. The new analysis, published in the journal Menopause, also revealed sleep and concentration significantly improved in the three-day window.
Comments | 0 ADD COMMENT
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018
International Conference on Molecular Biology and Stem Cells
Aug 13 - Aug 15, 2018